文献速递糖尿病

联合糖耐量异常与不确定血糖状态是高危囊性纤维化相关糖尿病新群体

Combined Indeterminate and Impaired Glucose Tolerance Is a Novel Group at High Risk of Cystic Fibrosis-Related Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

在Montreal和Lyon两个成人囊性纤维化前瞻性队列中,评估同时满足不确定血糖(INDET)和糖耐量受损(IGT)标准的患者是否糖尿病风险更高。结果显示INDET+IGT组无糖尿病生存率更低,CFRD风险从正常糖耐量者的17%升至INDET+IGT者的42%至56%,提示需更密切随访。

要点

  • 同时满足INDET和IGT标准的患者囊性纤维化相关糖尿病风险显著增高。
  • 正常糖耐量者CFRD风险约17%,INDET+IGT者达42%至56%。
  • 对INDET+IGT患者应考虑更密切的血糖随访。

核心结论

  • 同时满足INDET和IGT标准的患者发生囊性纤维化相关糖尿病的风险更高,可能需更密切随访。

研究设计与样本

  • Montreal囊性纤维化队列(MCFC)基线293例,排除基线已诊断CFRD后198例纳入前瞻分析。
  • Lyon囊性纤维化队列DIAMUCO共144例,其中105例纳入分析。
  • 两项均为前瞻性观察性队列研究。

主要发现

  • MCFC队列中,单纯IGT组和INDET+IGT组CFRD风险更高(P=0.0109)。
  • DIAMUCO队列中,INDET+IGT组无糖尿病生存率更低(P=0.0105)。
  • 两队列中CFRD风险从正常糖耐量者的17%升至INDET+IGT者的42%至56%。
  • MCFC平均年龄25.5±7.7岁,BMI 21.7±3.0 kg/m2,FEV1% 73.2±22.1,随访6.9±3.8年。
  • DIAMUCO平均年龄25.0±8.6岁,BMI 20.2±2.2 kg/m2,FEV1% 62.5±21.9,随访2.4±1.2年。

临床怎么用

  • 对同时符合INDET和IGT标准的囊性纤维化患者应加强血糖监测与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Indeterminate glycemia (INDET) and impaired glucose tolerance (IGT) are independently associated with cystic fibrosis-related diabetes (CFRD) risk. We determined whether patients meeting both criteria have increased risk of diabetes in 2 separate adult cohorts. METHODS: The Montreal Cystic Fibrosis Cohort (MCFC; n = 293 baseline and 198 for prospective analysis excluding subjects identified with incident CFRD at baseline) and the Lyon cystic fibrosis cohort [Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (DIAMUCO); n = 144/105] are prospective observational cohorts. RESULTS: In the MCFC and DIAMUCO cohorts, mean age was 25.5 ± 7.7 and 25.0 ± 8.6 years; body mass index, 21.7 ± 3.0 and 20.2 ± 2.2 kg/m2; percentage of forced expiratory volume expired in 1 sec, 73.2 ± 22.1 and 62.5 ± 21.9; and follow-up, 6.9 ± 3.8 and 2.4 ± 1.2 years, respectively. In the MCFC cohort, the IGT only and combined INDET and IGT (INDET + IGT) groups had greater risk of CFRD (P = 0.0109). In the DIAMUCO cohort, there was lower diabetes-free survival in the INDET + IGT group (P = 0.0105). In both cohorts, CFRD risk ranged from 17% in normal glucose tolerance patients up to 42% to 56% in patients with INDET + IGT. CONCLUSION: Patients who meet combined criteria have a higher risk of developing diabetes probably justifying closer follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Potter KJ, Reynaud Q, Boudreau V, et al. Combined Indeterminate and Impaired Glucose Tolerance Is a Novel Group at High Risk of Cystic Fibrosis-Related Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34132785. doi:10.1210/clinem/dgab384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。